lobbying_activities: 2340936
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2340936 | 342d36e3-73ba-4521-b954-8b883435e4d5 | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2019 | third_quarter | PHA | H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines. CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. Policies related to the reform of Medicare Part B and D specific to the price of prescription medications. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-10-13T09:10:22.420000-04:00 |